GlaxoSmithKline Pharmaceuticals Limited Share Price and Company Fundamentals
Last traded: Last Friday at 10:00 AM
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Key Metrics
PE ratio
44.85
PB ratio
21.13
Dividend yield
2.02%
Beta
0.08
Market cap
₹479.15B
Enterprise value
₹451.91B
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Full time employees | 3103 |
| Website | https://india-pharma.gsk.com |
| Mailing address | GSK House 252, Dr. Annie Besant Road Worli Mumbai 400030 India |
| Phone / Fax | 91 22 2495 9595 / 91 22 2495 9494 |
Dividends
Dividend yield
2.02%
Dividend amount
₹57.00
Payout ratio
90.40%
5Y Avg. yield
-%
GlaxoSmithKline Pharmaceuticals Limited paid ₹57.00 dividend and the ex-dividend date was 29 May 2026.The dividend payout ratio is 90.40%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GLAXO dividend payout ratio is between 70-90%. The lower dividend payout ratio is preferrable since it provides company margin to grow the dividends in future.
Company Executives
As of Sep 2026, following are the company executives and directors listed on GlaxoSmithKline Pharmaceuticals Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Bhushan Akshikar | MD & Executive Director | ||
| Mr. Ronojit Biswas | CFO & Whole-Time Director | ||
| Ms. Aparajita Rajput | Vice President of Technology | ||
| Mr. Ajay Avinash Nadkarni | VP of Administration & Real Estate and Company Secretary | ||
| Mr. Amit G. Pandey | Executive Vice President of Legal | ||
| Mr. Carson Dalton | Executive Vice President of Communications & Government Affairs | ||
| Mr. Harsh V. Trehan | Executive Vice President of Human Resources | ||
| Ms. Sukanya Choudhary | Executive Vice President of Regulatory Affairs | ||
| Dr. Shalini Menon | Executive Vice President of Medical Affairs | ||
| Mr. Rishikesh S. Jaiwant | Executive Vice President of Supply Chain Operations |
Profitability and management effectiveness
Profit margin
27.01%
Operating margin
29.80%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of GlaxoSmithKline Pharmaceuticals Limited is 479.15B and its enterprise value is 451.91B. The enterprise value to revenue ratio of GLAXO is 11.43. The enterprise value to EBITDA ratio of GLAXO is 33.98.
The GLAXO's stocks Beta value is 0.08 making it 92% less volatile compared to NSE market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Frequently Asked Questions
1. What is GlaxoSmithKline Pharmaceuticals Limited's Stock Symbol?
GlaxoSmithKline Pharmaceuticals Limited trades on NSE under the ticker symbol "GLAXO".
2. What is GlaxoSmithKline Pharmaceuticals Limited's stock price today?
One share of GLAXO stock can currently be purchased for approximately ₹2828.4.
3. How can I contact GlaxoSmithKline Pharmaceuticals Limited?
GlaxoSmithKline Pharmaceuticals Limited's mailing address is GSK House 252, Dr. Annie Besant Road Worli Mumbai 400030 India. The company can be reached via phone at 91 22 2495 9595.
4. What is GlaxoSmithKline Pharmaceuticals Limited's official website?
The official website of GlaxoSmithKline Pharmaceuticals Limited is https://india-pharma.gsk.com.